Laurus Labs Ltd. · NSE:LAURUSLABS
Laurus Labs — Q2 FY21 Earnings Presentation
23 slides from Laurus Labs's earnings presentation, Oct 29, 2020
Slide 1: Cover letter to stock exchanges
Laurus Labs Limited Corporate Office 2"d Floor. Serene Chambers. Road No. 7 Banjara Hills. Hyderabad - 50003~. Telangana. India T +91 ~0 6659 ~333, 3980 ~333. 23~2 0500 I 501 LAURUS Labs F +91 ~0 6659 ~320 I 3980 ~320 Knowledge . Innovation . Excellence October 29, 2020 To To The Corporate Relations
Slide 2: Laurus Labs Limited Q2 & H1 FY21 Investor Presentation
LAURUS LABS LIMITED Q2 & H1 FY21 INVESTOR PRESENTATION October 29, 2020 BSE: 540222 NSE : LAURUSLABS
Slide 3: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 4: Financial Snapshot – Q2 FY21
Financial Snapshot – Q2 FY21 ₹ Cr Revenue (YoY Gr 60 %) EBITDA (YoY Gr 172%) MARGIN % 33% 29% 1,139 974 23% 20% 21% 839 712 729 378 285 193 139 150 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 300 21% PAT (YoY Gr 325%) 21% EPS ₹ (face value ₹ 2/- per share) 18% 250
Slide 5: Business Snapshot
Business Snapshot - API -FDF Overview • Development, manufacture and sale • Developing and manufacturing oral • Contract development and manufacturing services for of APIs and Advanced Intermediates solid formulations for LMIC, North global pharmaceutical companies and several late stage • Leadershi
Slide 6: Segmental Revenue Breakup
Segmental Revenue Breakup ₹ Cr Generics API Generics FDF Synthesis 571 452 522 467 148 424 352 359 292 267 116 100 85 78 160 Q2 Q3 Q4 Q1 Q2 Q2 Q3 Q4 Q1 Q2 Q2 Q3 Q4 Q1 Q2 FY20 FY20 FY20 FY21 FY21 FY20 FY20 FY20 FY21 FY21 FY20 FY20 FY20 FY21 FY21 Q2 FY 21 Contribution • Generic API division showcased
Slide 7: Generic API Division
Generic API Division ₹ Cr Anti Viral API Onco API Other API 379 336 86 135 317 273 106 60 59 98 92 214 90 51 47 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q2 FY 21 Contribution 19% • Anti Viral API revenue showed a growth o
Slide 8: Generic FDF Division
Generic FDF Division ₹ Cr 452 352 292 267 160 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Generic FDF revenue showcased a robust growth of 183% YoY • RoW Markets – Launched TLE400 in the LMIC market • North America – Sales were driven by increased volumes in the US. Launched TLE400 & TLE600 in US • Comm
Slide 9: Synthesis (CDMO) Division
Synthesis (CDMO) Division ₹ Cr 148 116 100 85 78 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY22 • Revenue from Custom Synthesis division showed a growth of 36% (YoY) • Total Number of Active Projects in the CDMO division stood at 49 as on Q2 FY21 • Incorporated Wholly Owned Subsidiary to give increased foc
Slide 10: 5 year Division wise Revenue Contribution
5 year Division wise Revenue Contribution Generic 7% 2% 9% 10% FDF 3% 13% 8% 8% 8% 29% 6% 9% 38% 8% Custom Synthesis 10% 14% 10% Other API 11% 11% 82% 7% 77% 74% 7% 66% Onco API 39% 34% Anti Viral API FY 16 FY 17 FY 18 FY 19 FY 20 FY 21 H1 9
Slide 11: 5 years Return Ratios
5 years Return Ratios Pre Tax Return on Capital Return on Equity(2) (%) Net Debt/EBIDTA (3) (x) Employed(1) (%) 41.8% 37.5% 2.8x 2.2x 1.9x 1.9x 16.5% 17.4% 13.7% 14.1% 15.3% 11.9% 8.2% 6.2% 0.8x FY17 FY 18 FY 19 FY 20 H1 FY21 FY17 FY 18 FY 19 FY 20 H1 FY21 FY17 FY 18 FY 19 FY 20 H1 FY21 Note: Based
Slide 12: COVID – 19 Response
COVID – 19 Response Q2 FY21 saw normal levels of production, with rigorous safety, hygiene and cleaning protocols at all Manufacturing Facilities. Operations were at a steady state at Corporate Office and R&D center with all the scientist working onsite. Laurus Labs Priorities in the uncertain times
Slide 13: Manufacturing Facilities at Parawada, Vizag
Manufacturing Facilities at Parawada, Vizag Unit-I • Located at Jawaharlal Nehru Pharma City, Vishakhapatnam, India. • API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing. • Commenced operations in 2007. • 328 reactors with 1,226 Kilo Liters capacit
Slide 14: Manufacturing Facilities at Achutapuram, Vizag
Manufacturing Facilities at Achutapuram, Vizag • Located at APIIC, Achutapuram, Visakhapatnam, India. (SEZ) Unit-II • FDF and API manufacturing facility • Commenced operations in 2017. • FDF - capacity of 5 bn tablets/capsules per year. Capacity expansion initiated and will be operational by Decembe
Slide 15: Quality Focus & Regulatory Audits
Quality Focus & Regulatory Audits Facility Key Agencies Recent Inspection Year Kilo Lab – R&D USFDA 2016 – EIR received USFDA, WHO – Geneva, ANVISA, 2019 - 20 – EIR Received, Unit 1 COFEPRIS – Mexico and JZAMP Slovenia and cGMP certification received USFDA, WHO – Geneva, BGV Hamburg, 2019 - 20 – EIR
Slide 16: Strong R&D Capabilities
Strong R&D Capabilities R&D Centre - Hyd 166 160 134 114 85 7.4% 85 7.1% 5.6% 5.7% 4.8% 4.0% FY16 FY17 FY18 FY 19 FY 20 FY 21 H1 R&D Spend ₹ Cr % of Revenue Current Filings Status Therapy US ANDA Europe Canada Patents Patents ARV 15 4 5 DMFs Filed Granted Anti- Diabetic 3 3 2 Cumulative CVS 3 - - Fi
Slide 17: Outlook for FY21 & Beyond
Outlook for FY21 & Beyond Healthy Revenue visibility on the Changing business mix to drive Capacity augmentation to result back of robust Order Book growth in better return ratios • Partnership with Global Fund offers higher • Generic FDF segment contributed ~38% • Among top 5 in India in terms of v
Slide 18: Key Milestones
Key Milestones • Investment of INR 3000 mn by • Investment of INR Warburg Pincus • Crossed INR 20 billion of revenue 600 mn by FIL • Incorporated First • Commenced commercial operations • Set up the R&D Capital Subsidiary in USA. • Successfully listed on BSE &NSE from Unit 4 Centre at IKP, Managemen
Slide 19: Board of Directors & Leadership Team
Board of Directors & Leadership Team Executive Directors Name Background Dr Satyanarayana Chava Whole-time Director, Founder and Chief Executive Officer Ravi Kumar V V Whole-time Director and CFO Dr Lakshmana Rao C V Whole-time Director and Head, Quality Non-Executive Directors Name Background
Slide 20: Ownership Structure
Ownership Structure Corporate Structure All are 100% Subsidiaries Laurus Labs Limited India Sriam Labs Pvt Ltd. Laurus Holdings Ltd. Laurus Synthesis Laurus Generics SA India UK Pvt. Ltd (PTY) Limited Laurus Generics ^Laurus Generics Inc. GmbH. USA Germany Shareholding pattern * 32.12% 3.3% 20.7% 3.
Slide 21: Results Conference Call
Results Conference Call Results conference call on Friday October 30, 2020 at 11:00 AM IST Details of the conference call are as follows: Timing 11:00 am IST on Friday, October 30, 2020 Conference dial-in Universal Dial-In +91 22 6280 1214 India Local access Number +91 7045671221 Available all over
Slide 22: Contact us
Contact us About Laurus Labs Ltd. Laurus Labs is a leading research driven Pharmaceutical manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma and Gastroenterology .We are thri
Slide 23: Thank You
Thank You